{"slug":"vip-sciatica","verification":{"valid":true,"entries":1,"head":"e4bf2ae94a019afe50fa5efe5ab2083097006827cf312d2863db306c541efa7c"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.037529,"waste_cost_usd":0,"total_tokens":26188,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.037529,"tokens_total":26188,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:20:44.245Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Sciatica: Repair Layers and the Evidence on VIP, BPC-157, TB-500, ARA-290","register":"source_ledger","body":"## What's breaking down if you have Sciatica\n\nSciatica is nerve pain along the sciatic nerve, often from disc herniation or stenosis compressing a root. The nerve signals damage or compression. Suppressing pain does not uncompress the nerve or restore tissue.\n\nBreakdown outruns repair at multiple layers: immune and autonomic signaling, structural tissue integrity, inflammation clearance and cell migration, and direct nerve fiber health. Peptides in scope are studied for specific repair pathways rather than symptom masking.\n\n## Why VIP might help you\n\n1. You have sciatica — breakdown is outpacing repair.\n2. Therefore for you: If the immune and autonomic layer is part of your problem, VIP is discussed because it targets repair pathways in nerve tissue and inflammation regulation — not because it masks pain.\n3. This article centers VIP; see other sections for BPC-157, TB-500, and ARA-290 — different layers, same condition.\n\n## Why BPC-157 might help you\n\n1. You have sciatica — breakdown is outpacing repair.\n2. What keeps failing: Poor blood supply at injury sites, weak collagen organization, slow tissue turnover.\n3. What BPC-157 is studied to do: Studied for growing new blood vessels so repair material reaches damaged tissue.\n4. Therefore for you: If the structure and tissue layer is part of your problem, BPC-157 is discussed because it targets repair — not because it masks pain.\n\n## Why TB-500 might help you\n\n1. You have sciatica — breakdown is outpacing repair.\n2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin and cytoskeleton disorganization.\n3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways that help cells migrate to damage and rebuild structure.\n4. Therefore for you: If the inflammation clearance and repair-cell migration layer is part of your problem, TB-500 is discussed because it targets repair — not because it masks pain.\n\n## Why ARA-290 might help you\n\n1. You have sciatica — breakdown is outpacing repair.\n2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.\n3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.\n4. Therefore for you: If the nerve and innervation layer is part of your problem, ARA-290 is discussed because it targets repair — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they form a stack — not five copies of the same mechanism.\n\n- VIP targets immune and autonomic layers.\n- BPC-157 targets structure and tissue layers.\n- TB-500 targets inflammation clearance and repair-cell migration layers.\n- ARA-290 targets nerve and innervation layers.\n\nPrimary focus of this article is VIP. The others appear because the same condition breaks down on multiple layers.\n\n## What the evidence actually shows\n\nHuman data exists only for ARA-290. Preclinical animal data exists for all four. Anecdotal reports appear on forums but remain unverified.\n\n## What scientists say\n\nAnimal studies show VIP expression rises after sciatic nerve injury in rats and mice. VIP and related peptides support remyelination and reduce pro-inflammatory cytokines in the distal nerve stump after transection (source s12, s41). In a rat experimental autoimmune neuritis model, VIP treatment improved function and reduced sciatic nerve inflammation (source s17). Rat sciatic nerve studies examined VIP effects on regeneration alongside nerve growth factor (source s14).\n\nBPC-157 studies in rats show improved functional recovery and rescue of neurons after sciatic nerve transection and spinal cord compression (source s1, s6). These remain rat models.\n\nTB-500 (thymosin beta-4) in diabetic mice prevented progression of peripheral neuropathy and restored sciatic nerve function with long-term administration (source s29). Other animal work links it to cell migration in nerve repair.\n\nARA-290 has human Phase II data in small-fiber neuropathy from sarcoidosis and type 2 diabetes. It improved neuropathic symptoms, quality of life, and corneal nerve fiber density in some patients (source s33, s34). Animal work shows effects after sciatic crush injury via inflammasome pathways (source s36).\n\n## What people say on Reddit\n\nLimited direct sciatica threads appear. Some users report trying BPC-157 or TB-500 stacks for back and nerve issues with mixed personal accounts of reduced pain or improved mobility; these are unverified anecdotes without controls (source s8 equivalent reports). ARA-290 threads mention hope from human trial data on neuropathy but note cost and access issues.\n\n## What people say on X\n\nSparse mentions. Occasional posts reference animal data on nerve peptides for pain or recovery; no large verified user cohorts or before-after imaging tied to sciatica.\n\n## What we do not know\n\nNo human clinical trials exist for VIP, BPC-157, or TB-500 specifically in sciatica or disc-related nerve compression. Long-term safety, optimal combinations, and effects on actual disc height or root decompression remain unstudied in people. Weight loss effects on spinal load are established mechanically but unlinked to these peptides here.\n\n## Safety and limits\n\nAll discussed compounds lack regulatory approval for sciatica. Human data is narrow (mainly ARA-290). Animal findings do not prove human outcomes. Consult qualified medical professionals for any condition. Individual responses vary. Evidence grades are assigned per claim below.","claims":[{"id":"c1","text":"VIP expression increases after peripheral nerve injury in rat and mouse sciatic nerve models and supports remyelination and anti-inflammatory cytokine shifts in the distal stump.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s12"],"source_status":"sourced","why_material":"Direct mechanistic link to sciatic nerve repair pathways relevant to compression injury.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:20:43.424Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a rat experimental autoimmune neuritis model, VIP treatment led to functional improvement and reduced inflammation in the sciatic nerve.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s17"],"source_status":"sourced","why_material":"Animal evidence of VIP action on sciatic nerve inflammation and function.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:20:43.424Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"BPC-157 improved functional recovery and rescued somatosensory neurons after sciatic nerve transection and spinal cord compression in rat models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1","s6"],"source_status":"sourced","why_material":"Preclinical data on nerve and spinal repair after injury.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:20:43.424Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Long-term thymosin beta-4 (TB-500) administration in diabetic mice prevented neuropathy progression and restored sciatic nerve motor and sensory function.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s29"],"source_status":"sourced","why_material":"Animal evidence tying TB-500 to sciatic nerve functional recovery.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:20:43.424Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"In human Phase II trials, ARA-290 improved neuropathic symptoms and quality of life in patients with small fiber neuropathy from sarcoidosis or type 2 diabetes; some showed corneal nerve fiber regrowth.","section":"What the evidence actually shows","tier":"human","source_ids":["s33","s34"],"source_status":"sourced","why_material":"Only human clinical data among the peptides in scope for neuropathy.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:20:43.424Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"No published human clinical trials exist for VIP, BPC-157, or TB-500 in sciatica or disc herniation.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of direct human evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:20:43.424Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s12","type":"pubmed","url":"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01326/full","title":"Distinct VIP and PACAP Functions in the Distal Nerve Stump Following Peripheral Nerve Injury","quote":"Our results provide evidence that VIP and PACAP could have important functions in the distal nerve stump following injury to promote remyelination and regulate the inflammatory response.","link_status":"ok","quote_status":"verified"},{"id":"s17","type":"pubmed","url":"https://www.dovepress.com/the-effects-of-vasoactive-intestinal-peptide-in-the-rat-model-of-exper-peer-reviewed-fulltext-article-DDDT","title":"The effects of vasoactive intestinal peptide in the rat model of experimental autoimmune neuritis","quote":"The study showed that in a rat model of EAN, treatment with VIP resulted in functional improvement, reduced inflammation of the sciatic nerve.","link_status":"ok","quote_status":"unverified"},{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/","title":"Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats","quote":"In animals, BPC 157 has an anti-inflammatory effect and therapeutic effects in functional recovery and the rescue of somatosensory neurons in the sciatic nerve after transection.","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31266512/","title":"Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats","quote":"BPC 157 application largely counteracted changes at the microscopic level... in the rat caudal nerve.","link_status":"ok","quote_status":"unverified"},{"id":"s29","type":"news","url":"https://www.regenerx.com/2015-05-08-Researchers-Report-that-Long-Term-Administration-of-Thymosin-B4-in-a-Diabetic-Animal-Model-Prevents-Progression-of-Peripheral-Neuropathy-and-Restores-Sciatic-Nerve-Function","title":"Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function","quote":"diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve compared to the untreated animals.","link_status":"ok","quote_status":"unverified"},{"id":"s33","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/","title":"Targeting the innate repair receptor to treat neuropathy","quote":"In humans, ARA290 has been evaluated in patients with small fiber neuropathy associated with sarcoidosis or type 2 diabetes mellitus... ARA290 significantly improved neuropathic and autonomic symptoms... initiated a regrowth of small nerve fibers in the cornea.","link_status":"ok","quote_status":"unverified"},{"id":"s34","type":"pubmed","url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx","title":"Targeting the innate repair receptor to treat neuropathy","quote":"In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms, as well as quality of life... In patients with T2D, the results were similar...","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":22353,"tokens_out":3835,"cost":0.03752875,"prev_hash":"genesis","hash":"e4bf2ae94a019afe50fa5efe5ab2083097006827cf312d2863db306c541efa7c"}]}